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Abbreviations: 
5?FU:  5?Fluorouracil  
BRAF:  v?Raf murine sarcoma viral oncogene homolog B   
CISH:   chromogen ISH 
CRC:  colorectal cancer (colorectal adenocarcinoma) 
FFPE:  formalin?fixed paraffin embedded 
EGFR:  epidermal growth factor receptor 
ERBB2: erb?B2 receptor tyrosine kinase 2 
FGFR:  fibroblast growth factor receptor 
FISH:  fluorescence ISH  
HER2:  human epidermal growth factor receptor 2 
IHC:  immunohistochemistry  
ISH:  in situ hybridization 
KRAS:  v?Ki?ras2 Kirsten rat sarcoma viral oncogene homolog 
MAPK:  mitogen?activated protein kinase 
MET:  tyrosine?protein kinase met/hepatocyte growth factor receptor 
MLH1:  mutL homolog 1 
MMR(d): DNA mismatch repair (deficiency) 
MSH2:  mutS protein homolog 2 
MSH6:  mutS homolog 6 
MSI (?h): microsatellite instability (?high) 
NGS:  next?generation sequencing 
NKI:  netherlands cancer institute 
NRAS:  neuroblastoma RAS viral oncogene homolog 
OS:  overall survival 
PD?L1:  programmed death?ligand 1 
PDGFRA: platelet derived growth factor receptor alpha 
PI3K:  phosphoinositide 3?kinase 
PIK3CA: phosphatidylinositol?4,5?bisphosphate 3?kinase catalytic subunit alpha 
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PMS2:  postmeiotic segregation increased 2 
RAF:  rapidly accelerated fibrosarcoma 
RFS:  recurrence?free survival 
SCC:  squamous cell carcinoma 
SNP:  single nucleotide polymorphism 
TCGA:  the cancer genome atlas 
TERT:  telomerase reverse transcriptase 
TP53:  tumor protein p53 
TPS:  tumor proportion score 
UC:  urothelial carcinoma 
UrC:  urachal cancer 
WHO:  world health organization 
 
Novelty and Impact 
The largest cohort of urachal cancer (UrC) so far underwent targeted sequencing and assessment of 
MMR?/MSI? and PD?L1?status. These analyses might provide a basis for targeted and/or immune?
therapy approaches. Aberrations in intracellular signal transduction pathways (RAS/RAF/PI3K) were 
detected in 31% of cases, in addition to (HER2), , 	
, and 	alterations with 
potential therapeutic implications. MMR?deficiency/MSI?high?status was absent. Still, anti?PD?1/PD?L1?
immunotherapy approaches could be tested as a subset of 16% of cases showed PD?L1?expression. 
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Abstract 
Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages 
requiring systemic treatment. Although cytotoxic chemotherapy is of limited effectiveness, prospective 
clinical studies can hardly be conducted. Targeted therapeutic treatment approaches and potentially 
immunotherapy based on a biological rationale may provide an alternative strategy. We therefore 
subjected 70 urachal adenocarcinomas to targeted next?generation sequencing, conducted  and 
immunohistochemical analyses (including PD?L1 and DNA mismatch repair proteins (MMR)) and 
evaluated the microsatellite instability (MSI) status. The analytical findings were correlated with 
clinicopathological and outcome data and Kaplan?Meier and univariable/multivariable Cox regression 
analyses were performed. The patients had a mean age of 50 years, 66% were male and a 5?year 
overall survival (OS) of 58% and recurrence?free survival (RFS) of 45% was detected. Sequence 
variations were observed in  (66%),  (21%),  (4%),  (4%), 	
 (1%),  
(1%),  (1%), and 	(1%). Gene amplifications were found in 	(5%), (2%) 
and (2%). We detected no evidence of MMR?deficiency (MMR?d)/MSI?high (MSI?h), whereas 10 
of 63 cases (16%) expressed PD?L1. Therefore, anti?PD?1/PD?L1 immunotherapy approaches might 
be tested in UrC. Importantly, we found aberrations in intracellular signal transduction pathways 
(RAS/RAF/PI3K) in 31% of UrCs with potential implications for anti?EGFR therapy. Less frequent 
potentially actionable genetic alterations were additionally detected in (HER2), ,	
, 
and 	The molecular profile strengthens the notion that UrC is a distinct entity on the genomic 
level with closer resemblance to colorectal than to bladder cancer. 
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Introduction 
Urachal cancer (UrC) is a rare but aggressive cancer. It is derived from the urachus, an embryological 
structure extending from the allantois to the fetal bladder. The urachus usually degenerates to form a 
fibromuscular cord running from the dome of the urinary bladder to the umbilicus, where it forms the 
median umbilical ligament. Incomplete obliteration occurs in up to 32% of adults but is usually 
microscopic and asymptomatic. 
1
 
Approximately 90% of UrC are adenocarcinomas that show remarkable histomorphological similarities 
with both primary bladder adenocarcinoma and colorectal adenocarcinoma (CRC), which represent 
the main differential diagnostic entities. 
2
 The correct differentiation of these entities is important, as 
therapeutic options differ. While localized UrC is usually treated by partial cystectomy and    
removal of the umbilical ligament and umbilicus, primary bladder adenocarcinoma usually requires 
radical cystectomy, and CRC growing into the bladder requires either additional surgical management 
of the primary tumor or palliative management.  
A significant proportion of UrC cases require further therapy due to recurrent and/or metastatic 
disease in 21% to 48%. 
2
 This calls for effective systemic therapy regimes, while radiotherapy has only 
a limited role. 
3
 Chemotherapy has traditionally been chosen in analogy to urothelial bladder cancer 
due to its close anatomical relation. However, non?bladder cancer inspired regimens including 5?
Fluorouracil (5?FU) like in CRC show more favorable characteristics in advanced UrC. 
2
 
In addition, recent molecular data and positive results from the first targeted therapies point towards 
therapeutic similarities between UrC and CRC. Like in CRC, oncogenic signaling in UrC appears to 
employ preferably the epidermal growth factor receptor (EGFR)/mitogen?activated protein kinase 
(MAPK) and phosphoinositide 3?kinase (PI3K) pathways. Moreover, anti?EGFR agents such as 
cetuximab seem to exert positive effects. 
4?6
  
To date, genetic data on UrC still is scant or reported only in few cases. 
4, 5, 7?12
 In addition, data on 
non?adenocarcinoma UrC is completely lacking. We therefore analyzed a large cohort of urachal 
adenocarcinomas in a targeted sequencing approach supplemented with   and protein 
expression analyses including evaluation of PD?L1 expression and evaluation of the MMR/MSI status. 
In addition, a small subset of non?adenocarcinoma UrCs was also analyzed. We aimed to gain more 
insight in potentially targetable molecular alterations of UrC to eventually facilitate targeted therapy 
and/or immunotherapy decision?making.
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Material and Methods 
Cohorts and clinicopathological data 
Due to the rarity of UrC, an international, multi?institutional approach was chosen and two cohorts 
were created.  
The first cohort included formalin?fixed paraffin embedded (FFPE) urachal adenocarcinoma samples 
from 41 patients from nine centers: University Hospital Essen (Germany) 
4
, Semmelweis University 
Budapest (Hungary), University of Göttingen (Germany), University Hospital/RWTH Aachen University 
(Germany), University of Bonn (Germany), Jagiellonian University Cracow (Poland), University 
Hospital of Rennes (France), Institute of Pathology of Trier (Germany), and the Vancouver Prostate 
Center (Canada). Additionally, 4 cases of non?adenocarcinoma histology (n=2: squamous cell 
carcinoma (SCC); n=1: urothelial carcinoma (UC), n=1: undifferentiated carcinoma) were available and 
analyzed. 
The second, national Dutch cohort included FFPE samples from 29 patients with urachal 
adenocarcinomas from the Netherlands Cancer Institute (NKI) in Amsterdam (The Netherlands).  
Diagnosis of urachal cancer was established after consideration of multi?disciplinary results. 
Histopathology was evaluated in accordance with (adapted) WHO?criteria 
13?15
 and review of available 
material was conducted. Data was requested from cooperating institutions using a standardized 42 
parameter datasheet.  
The first international multi?institutional cohort was analyzed at the University Hospital Essen (Institute 
of Pathology) and the second national Dutch cohort at the Netherlands Cancer Institute (NKI) in 
Amsterdam. 
Clinicopathological data was collected retrospectively by chart review and from epidemiological 
databases. Clinical follow?up of patients varied by tumor stage and individual institutional routines. 
Overall survival (OS) was defined as the time from diagnosis to death from any cause. Recurrence?
free survival (RFS) was defined as the time to occurrence of metastatic disease and/or local 
recurrence. The study is in accordance with the principles embodied in the Declaration of Helsinki. It 
was approved before start of experiments by the ethics committee of the Medical Faculty of the 
University of Duisburg?Essen (16?6902?BO) and included collection of external tumor samples for 
analyses. The Translational Research Board of the Netherlands Cancer Institute – Antoni van 
Leeuwenhoek Hospital (CFMPB310) additionally approved analysis of the Dutch cohort. 
 
Targeted next"generation sequencing (NGS) 
Customized NGS panels were used to cover important known actionable driver mutations/alterations 
from CRC, UC and additional main cancer entities (15/13 gene panels; Suppl. Tables S1?S3). 
A detailed description of sample processing, DNA extraction, sequencing and data analysis can be 
found in Suppl. Document S1. In brief, in both cohorts representative FFPE tumor tissue blocks were 
selected and DNA was extracted. After target enrichment, libraries were sequenced on an Illumina 
MiSeq platform (first cohort, Essen) and Illumina Hiseq 2500 platform (second cohort, Amsterdam) 
followed by mapping to the human genome (version hg19), data filtering and reporting of all non?
benign, non?SNP variants found in Cosmic and/or Clinvar (selection of pathogenic alterations). 
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In situ hybridization (ISH) assays 
In cases with evidence for gene amplification detected by NGS (fold change: ≥3.5) in the first cohort, 
the findings were validated by ISH (! chromogen ISH (CISH), 	": fluorescence ISH 
(FISH)) followed by immunohistochemistry (IHC). Further details can be found in Suppl. Document S1.  
 
Immunohistochemistry  
p53?IHC analyses were done from available FFPE material from the cohort of Essen (n=12). PD?L1 
analyses were performed using clone 22C3 and MMR?status was determined by MLH1?, MSH2?, 
MSH6, and PMS2?IHC. MMR?IHC results of a subset of cases (n=12) has been published. 
16
 Due to 
the limited amount of tissue available, further IHC?assays (HER2, EGFR, c?MET) were restricted to 
cases with signs of gene amplification in NGS? and ISH?analyses. Further details can be found in 
Suppl. Document S1 and Suppl. Table S4. 
 
Microsatellite instability (MSI) analyses 
In brief, multiplexed PCRs were performed using 5 primers. MSI?h was defined as the presence of 2 or 
more unstable microsatellite markers. Further details can be found in Suppl. Table S5. 
 
Statistical analyses 
Statistical analyses were conducted with SPSS (v23; IBM, Armonk, USA). The Chi²?test, t?test or 
Spearman correlation was used when appropriate. Kaplan?Meier survival analyses with the log?rank 
test were performed to assess the impact of selected variables on OS and RFS. In addition, 
univariable/multivariable Cox regression analyses were conducted (inclusion criteria for multivariable 
analysis: p≤0.05 in univariable analysis). P?values ≤0.05 were assumed statistically significant, while 
p?values ≤0.1 were designated as trends. Genetic alterations were visualized using the OncoPrinter 
(v.1.0.1) and MutationMapper (v1.0.1) tools. 
17, 18
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Results 
Clinicopathological and prognostic characteristics of urachal adenocarcinomas 
Detailed clinicopathological and survival data of the 70 analyzed urachal adenocarcinomas are shown 
in Tables 1 and 2. Both cohorts were well?balanced in terms of clinicopathological characteristics. 
Data on follow?up was available in 64 of the 70 patients (91.4%) with urachal adenocarcinomas. The 
median follow?up was 49 months (range: 2?212 months). The 5?year OS and RFS rates were 58% and 
45% respectively, with a median OS of 109 months (SE: 29.9) and median RFS of 50 months (SE: 
13.0). 
 
Genomic alterations in urachal adenocarcinomas 
Detailed information is shown in Figure 1, Suppl. Document S1, Suppl. Figure S1 and Suppl. Table 
S2. 
Overall, 73 pathogenic mutations and four gene amplifications were detected in the 70 analyzed 
urachal adenocarcinomas. At least one genomic alteration was found in 55 of 70 patients (79%). All 
reported mutations were predicted to be pathogenic. 
Missense mutations were the most common type of alteration (n=64), followed by truncating mutations 
(n=4), and nonsense mutations (n=2). There was one deletion, one insertion and one splice?site 
mutation. 
Two of the four patients with gene amplifications were female (50%), three were intestinal type UrC 
(	#amplified: n=2, ?amplified: n=1), one was a signet ring cell type UrC (?amplified) 
(Suppl. Figure S2) and all were alive at last follow?up.  
Activating MAPK/PI3K?alterations were common events in urachal adenocarcinomas with 22 
mutations in #",  or  affecting 22 of 70 patients (31%) (Figure 1, Suppl. Figure 
S1). These alterations were mutually exclusive, whereas in 16 of 22 cases (73%) a concomitant TP53 
mutation was detected. All mutations affected functional regions with predicted pathogenicity (Suppl. 
Figure S1).  
The first, multi?institutional cohort showed more  mutations ($%&&'). No other significant 
differences regarding molecular alterations between both cohorts were noted. In particular, there were 
no statistically significant differences in clinico?pathological or in any molecular parameters between 
mucinous and intestinal type urachal carcinomas. 
In 66 of 70 cases (94.3%) tissue for MMR?IHC was available with technical feasibility of IHC of all four 
proteins (MLH1, MSH2, MSH6, PMS2) in 61 of 70 cases (87.1%). The molecular MSI?analyses were 
feasible in 56 of 70 cases (80%). A negative MMR expression was detected in one case (MSH2). In 
this and all other cases, all remaining MMR?markers were positive and no MSI?h was detected.  
In 63 of 70 cases (90%) sufficient material was available for PD?L1?IHC. In 10 of these 63 cases 
(15.9%) a specific PD?L1?expression in the tumor cells was detectable (Figure 1) with a tumor 
proportion score (TPS) of 1?49% in 9 of 10 cases (90%) and a TPS ≥ 50% in one case (10%). PD?L1?
expression was not restricted to intestinal type UrC (3/10; 30%). The majority of PD?L1 expressing 
cases were found in mucinous type UrC (7/10; 70%) including the only case with high PD?L1?
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expression (TPS ≥ 50%). No obvious clustering of cases with PD?L1?expression and other molecular 
events was obvious. However, both cases with ?alterations showed PD?L1 expression.  
 
Correlation between genomic alterations and clinical outcomes  
Clinicopathological factors were not associated with any genetic event, except for a trend to higher 
Mayo tumor stage in UrC with MAPK/PI3K?alterations ($%&&(). Organ confined disease, i.e. 
Sheldon
19
 stage ≤IIIA and Mayo
20
 stage I, and absence of metastatic disease were univariable 
predictors of more favorable OS ($%&&)$%&&
)$%&&("$%&&
) while only absence of lymph 
node metastasis predicted better RFS ($%&&&*+ in univariable analysis. A trend to more favorable 
RFS was found in intestinal type UrC ($%&&(,log?rank test: $%&&)-, Suppl. Figure S3+and in organ 
confined disease in the Mayo system ($%&&)+  
Presence of PD?L1 expression was associated with adverse PFS ($%&&&; log?rank test), however, 
there were only 3 events in the PD?L1 positive group, thus limiting its significance. No such association 
was detected regarding OS. 
In multivariable Cox?analyses for OS and RFS, presence of any mutation or MAPK/PI3K?alteration did 
not exhibit prognostic influence (Table 2).  
Additionally, no correlation was observed between the mutational status of  and its IHC staining 
pattern. A higher rate of  mutation was observed in UrC with signet ring cells ($%&&). No other 
clinicopathological or prognostic associations were noted for  and/or mutational status. 
 
 
Results in non"adenocarcinoma UrC 
The results of the four cases of non?adenocarcinoma UrC are included in Figure 1 and Suppl. Table 
S2.  Due to the low number of cases, no correlation analyses with clinicopathological data were 
performed. 
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Discussion 
Systemic therapy is often required in UrC because patients present with advanced stage disease or 
they progress after initial locoregional intervention. Investigation of the efficacy of chemotherapy has 
been limited to retrospective series. Due to the rarity of UrC, it is not feasible to perform large 
prospective clinical studies to evaluate the clinical benefit of various systemic therapies. Molecular 
alterations, however, may provide the rationale for targeted therapeutic approaches and/or 
immunotherapy. 
The most common genetic alterations in urachal adenocarcinomas we detected were mutations 
(66%). This high number indicates the common role of inactivation of this tumor suppressor gene also 
in UrC. Although  has in the past been considered mostly undruggable, recently multiple efforts 
of targeting altered tumors are in development.
21
 
In addition, we found a subset of UrC characterized by dysfunctional and activated oncogenic MAPK? 
and PI3K?pathways. 
4, 5
 As EGFR signaling mainly occurs through these pathways 
6
, we grouped 
together all UrC with any pathogenic mutational event in    or  (n=22; 
31%). This subset is additionally equivalent to all UrCs with mutations in intracellular signal 
transduction pathways and was termed ‘MAPK/PI3K?altered’ subset. All these alterations were 
mutually exclusive. 
These findings together with the results of the MMR?/MSI? and PD?L1?analyses have important 
therapeutic and ontogenetic implications. 
Due to histopathological and certain clinical similarities of UrC and CRC, chemotherapy in advanced 
UrC has often been adapted from CRC with 5?FU containing approaches. This has been shown to be 
more effective compared with regimes used for UC. 
2, 22
 In accordance with this observation, we did 
not find evidence of MMR?d/MSI?h in UrC, which leads to a hypermutated phenotype and in CRC has 
been implicated in decreased 5?FU?efficacy.
23
 Our single UrC?case with immunohistochemical MSH2?
loss seems to represent a false negative result, as MSH6?protein expression was retained which 
should not be the case in MSH2?deficient tumors.
7
 Additionally, no evidence of MSI?h was detected on 
the DNA level by microsatellite PCR analyses neither in this nor in any other case.  
Another recent and efficient anti?cancer strategy is targeting tumoral immune?escape mechanisms, in 
which inhibitors of the PD?1/PD?L1?axis are of particular therapeutic interest. PD?1/PD?L1 inhibitors 
have proven efficacy in several types of advanced cancer, including melanoma, non?small?cell lung 
cancer, renal cell carcinoma and bladder cancer.
24
 In most studies, cases with immunohistochemical 
PD?L1?expression on tumor cells and/or tumor?related immune?cells showed better responsiveness to 
PD?1/PD?L1?inhibitors. However, as also in tumors without PD?L1?expression positive anti?tumoral 
effects can be detected, PD?L1?IHC testing is considered complementary with the exception of the 
companion diagnostic 22C3?test in NSCLC.
24
 With regard to UrC, these results implicate that PD?
1/PD?L1?inhibitors might be effective in advanced disease despite its modest rate of PD?L1?expression 
(16%). In fact, others have recently reported on a case in UrC with atezolizumab?therapy, an anti?PD?
L1?antibody, resulting in stable disease.
25
 However, as MMR?d/MSI?h does not seem to be a hallmark 
of UrC at least in our cohort, immune escape mechanisms employing the PD?1/PD?L1 axis do not 
seem to be the defining molecular characteristic of UrC. This also has implications for the use of 
Page 11 of 23
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
11 
 
pembrolizumab in UrC, an anti?PD?1?antibody, which recently gained FDA?approval in MMR?d/MSI?h 
tumors irrespective of site of origin.  
Therefore, targeted therapy approaches are of prominent therapeutic interest in advanced UrC. 
Recently, ./#0123 and colleagues reported a successful application of cetuximab, an anti?
EGFR monoclonal antibody which is used in metastasized CRC, in one UrC patient who was 
pretreated with chemotherapy. This treatment was justified by the presence of an 	 amplification 
and absence of a  mutation. 
5
 
In CRC, it has been shown that MAPK?/PI3K?activation downstream of the EGF receptor is associated 
with anti?EGFR therapy resistance. 
26
 We detected two cases in our cohort with coexisting 	 gene 
amplification and without activating MAPK?/PI3K?mutations thus 	 amplification is a rare event in 
UrC. Therefore, it seems reasonable to test for 	 gene amplifications and activating MAPK/PI3K?
pathway mutations in advanced UrC when an anti?EGFR therapy is considered. This approach would 
be similar to the concept of complementary/companion diagnostics in CRC. 
27
 
In addition to these therapeutic considerations, the mutational profile of UrC shows similarities to that 
of CRC. Most of the detected activating MAPK/PI3K?pathway mutations were also common in CRC 
when compared to The Cancer Genome Atlas (TCGA) data. 
28
 This is especially prominent in the 
clustering of codon G12/G13  alterations but also for the remaining , , and  
mutations (Suppl. Figure S1). 
28
 Interestingly, both 	 amplified cases we detected were intestinal 
type UrCs. 
However, not only similarities but also differences were detected. For example, we identified three 
non?classical,  mutations (G469A: n=1, D594G: n=2) adding to the four classical V600E 
mutations reported previously. 
4
 While the G469A  mutation was relatively common in cancer, 
the D594G variant has rarely been detected in cancer.  Interestingly, although being located in the 
BRAF?kinase region, the D594G variant has been described in a case of metastatic CRC responding 
to cetuximab. 
27
 
In addition, a comparison with TCGA data for CRC revealed lower frequencies of almost all analyzed 
genetic alterations in UrC with the exception of  mutations. (Suppl. Figure S4). 
28
 However, 
although certain differences to CRC are apparent, the disparity to UC is more pronounced (Suppl. 
Figure S4). This notion is further supported by the very low incidence of Telomerase reverse 
transcriptase () promoter mutations in urachal adenocarcinomas (4%), which is otherwise a very 
common event in UC but not in CRC. 
29?31
 Interestingly, our findings regarding MMR?d/MSI?h in UrC 
are more comparable to figures in UC
32
 than in CRC
23, 28
. Regarding the rate of PD?L1?expression, 
UrC (16%) seems to be in the lower range of figures reported for UC (14%?28%)
33
 and CRC (9%?
43%).
34, 35
 Taken together, UrC appears to be a distinct entity on the genomic level with closer 
resemblance to CRC than to UC. Further analyses are needed to address this issue while the present 
study was not primarily designed from an ontogenetic point of view. 
In addition to alterations related to intracellular signal transduction pathways, we also detected cases 
with other pathogenic and possibly targetable genetic events. For example, pathogenic 	
, , 
and 	A mutations and ? and ?gene amplifications were detected in one case each, 
possibly identifying therapeutic targets in these patients.  
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Interestingly, both UrC?cases with ?alterations exhibited PD?L1?expression and first (pre?)clinical 
evidence of the relationship between PD?L1 upregulation and ?alterations is emerging.
36
 
Moreover, one case with high level  gene amplification and HER2?protein expression was 
detected (Suppl. Figure S2). HER2 is another member of the EGFR family and a well?known 
therapeutic target in breast and gastric cancer and under clinical investigation in other cancers such as 
non?small cell lung cancer. 
37?39
  
Our analysis has certain limitations. Due to the rarity of the disease, prospective analyses can hardly 
be conducted. We therefore chose a retrospective multi?institutional approach to maximize our sample 
size. In addition, we analyzed a first multi?institutional, international cohort and a second national 
Dutch cohort at different sites. Through this approach we expected to gain a more comprehensive and 
homogenous estimation of genetic events in UrC. This approach holds, however, the disadvantage of 
analytical differences between laboratories. This applies to the use of MiSeq and HiSeq?platforms at 
the different sites. While the enhanced capabilities and sensitivity of the HiSeq?platform are accepted, 
both sites were in contact to obtain best comparable analytic data. Although our cohort is the largest 
analyzed in the literature, the case number is still low, which precludes adequate statistical power for 
some sub?group analyses. This is also important when considering the results of survival analyses as 
inevitably the samples were collected from patients with a range of different stages and treatments 
confounding the possible survival impact of genetic alterations. Additionally, the employed gene panel 
was of modest size which has to be kept in mind in regard to the patients where no genomic 
aberration was detectable. 
In conclusion, we have analyzed the largest cohort of UrC to date in an international, multi?institutional 
targeted sequencing approach supplemented with   hybridization and protein expression 
analyses including evaluation of PD?L1 expression and MMR/MSI?status. Although MMR?d/MSI?h 
does not seem to be a hallmark of UrC, anti?PD?1/PD?L1 immune therapy might be a potential 
therapeutic option given the PD?L1 expression rate in UrC. In particular, our results underline the role 
of MAPK/PI3K?pathway dysregulation which was detected in 31% of urachal adenocarcinomas. This 
has important implications for possible anti?EGFR therapy in UrC and suggests that targeted testing of 
MAPK/PI3K?pathway alterations would be reasonable in patients with advanced UrC before 
considering anti?EGFR therapy. In addition, further potentially druggable alterations were found in 
(HER2), , 	
, and 	 in a subset of patients. Our data support the notion of 
UrC being a distinct entity on the genomic level with closer resemblance to CRC than to UC.  
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Table 1 n (%) 
  
Any mutation MAPK/PI3K alterated 
yes 
(n) 
 yes 
% 

yes 
(n) 
 yes 
% 

Sex 
Female 24 (34%) 18 75% 
&'&
9 38% 
&*Male 46 (66%) 25 76% 13 28% 
Total 70 53 76% 22 31% 
Age median (min, 
max) 
50 (24, 
78) 
? #   #
UrC type 
Intestinal 30 (43%) 24 80% 
&*''
10 33% 
&-*)
Mucinous 26 (37%) 18 69% 8 31% 
NOS 5 (7%) 4 80% 1 20% 
Signet 
ring 
4 (6%) 4 100% 1 25% 
Mixed 5 (7%) 3 60% 2 40% 
Total 70 53 76% 22 31% 
Signet ring 
cells 
Yes 11 (17%) 10 91% 
&&
3 27% 
&(No 55 (83%) 40 73% 18 33% 
Total 66 50 76% 21 32% 
Sheldon 
I 0 (0%) 0 0% 
&
)
0 0% 
&)&'
II 8 (12%) 5 63% 2 25% 
IIIA 28 (41%) 20 71% 10 36% 
IIIB 5 (7%) 3 60% 1 20% 
IIIC 1 (2%) 1 100% 1 100% 
IIID 1 (2%) 1 100% 0 0% 
IVA 5 (7%) 4 80% 1 20% 
IVB 20 (29%) 17 85% 5 25% 
Total 68 51 75% 20 29% 
Mayo 
I 17 (28%) 10 59% 
&&(
4 24% 
&-((
II 19 (31%) 14 74% 8 42% 
III 5 (8%) 4 80% 1 20% 
IV 20 (33%) 17 85% 5 25% 
Total 61 45 74% 18 30% 
LN status 
N0 28 (48%) 19 68% 
&

9 32% 
&'*
N+ 12 (21%) 10 83% 4 33% 
No LND 18 (31%) 15 83% 

5 28% 

Total 58 44 76% 18 31% 
Dist. met. 
M0 42 (68%) 31 74% 
&
13 31% 
&('M+ 20 (32%) 17 85% 5 25% 
Total 62 48 77% 18 29% 
 
Table 1) Clinicopathological data in relation to mutational data 
Mutational data is separately displayed for cases with any detected mutation and for cases with 
MAPK/PI3K?pathway activation (mutations in intracellular signal transduction pathways). 
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Detailed clinicopathological data separately displayed for both cohorts can be found in Suppl. Table 
S3. 
UrC: urachal cancer, LN: lymph node, Dist. met.: distant metastasis, NOS: not otherwise specified, 
LND: lymph node dissection 
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Table 2a Overall survival (OS) Recurrence"free survival (RFS) 
   HR 95% CI  HR 95% CI 
Sex 
female 14     14     
male 0.801 0.327?1.958 &)) 1.462 0.591?3.614 &*


Age 
≤50 years 14     14     
>50 years 0.725 0.319?1.647 &** 0.607 0.282?1.304 &&

Type intestinal 
no 14     14     
yes 0.589 0.253?1.369 &
- 0.488 0.222?1.074 &&(
Type mucinous 
no 14     14     
yes 1.649 0.740?3.677 & 1.189 0.566?2.497 &)*-
Signet ring 
cells 
no 14     14     
yes 2.148 0.832?5.548 &

* 1.725 0.685?4.345 &*(
Sheldon stage 
≤IIIa 14     14     
>IIIb 2.405 1.060?5.456 &&) 1.801 0.858?3.782 &
&
Mayo stage 
I 14     14     
≥II 4.497 1.320?15.313 &&
) 2.513 0.943?6.696 &&)
LN status 
N0 14     14     
N+ 2.888 1.065?7.828 &&( 4.565 1.615?12.902 &&&*
Dist. met. 
M0 ref.     14     
M+ 2.43 1.085?5.441 &&
 1.564 0.701?3.493 &(
Any mutation 
no 14     14     
yes 2.56 0.762?8.596 &
- 0.922 0.390?2.180 &-*
MAPK/PI3K 
alterated 
no 14     14     
yes 0.812 0.320?2.061 &))
 0.897 0.396?2.033 &('
                
Table 2b Overall survival (OS)   Recurrence"free survival (RFS) 
    HR 95% CI    HR 95% CI 
Sheldon stage (≤IIIa/>IIIb) 2.203 0.965?5.026 &&)
 LN Stage (N0/N+) 2.462 0.757?8.013 &
*
Any mutation (no/yes) 2.216 0.653?7.517 && Any mutation (no/yes) 1.343 0.279?6.471 &(

               
Sheldon stage (≤IIIa/>IIIb) 2.384 1.043?5.450 &&' LN Stage (N0/N+) 2.841 0.836?9.663 &&'*
MAPK/PI3K altered (no/yes) 0.931 0.363?2.391 &-- MAPK/PI3K altered (no/yes) 0.362 0.067?1.945 &)
               
Mayo stage (I/≥II) 4.035 1.171?13.909 &&( "     
Any mutation (no/yes) 1.81 0.525?6.243 &*- "     
                
Mayo stage (I/≥II) 4.563 1.337?15.577 &&
 "     
MAPK/PI3K altered (no/yes) 0.846 0.326?2.196 &( "     
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Table 2) Univariable (a) and multivariable (b) Cox"analyses in the total cohort of urachal adenocarcinomas 
OS?related multivariable analysis models were calculated for Sheldon and Mayo stages separately (both p<0.05 in univariable analysis). As both staging 
systems include information on status of lymph nodes and distant metastasis, these factors were excluded from OS?related models. For RFS, only lymph 
node status exhibited a p?value <0.05 in univariable analyses. Therefore, RFS models have been calculated separately including lymph node status. 
HR: hazard ratio, CI: confidence interval, LN: lymph node, Dist. met.: distant metastasis
Figure legends 
 
Figure 1) Oncoprints of the genetic alterations in UrC 
A) Overview of the genetic alterations detected in the total cohort urachal adenocarcinomas. B) A more detailed version including information on gender, 
histology, PD?L1 expression and genetic alteration type also in the non?adenocarcinoma UrC cases. Gene amplifications (including 5, n=41/70) were 
evaluated in the first cohort only. Details on the genetic events can be found in Suppl. Table S2. 
NOS: not otherwise specified, SCC: squamous cell carcinoma, TPS: PD?L1 tumor proportion score, UC: urothelial carcinoma, UD: undifferentiated carcinoma. 
mucinous*: cases with predominant signet ring cell morphology included 
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SUPPLEMENTARY MATERIAL  
 
Supplementary Table S1) Customized gene panel for targeted sequencing in UrC 
The panel was customized to include known driver mutations/alterations in colorectal cancer, urothelial cancer 
and other main cancer entities. 
Abbreviations: BRAF: v?Raf murine sarcoma viral oncogene homolog B, DDR2: discoidin domain?containing 
receptor 2, EGFR: epidermal growth factor receptor, ERBB2: Erb?B2 Receptor Tyrosine Kinase 2/HER2/neu, 
FGFR1/3: fibroblast growth factor receptor 1/3, HRAS: Harvey Rat Sarcoma Viral Oncogene Homolog, KIT: 
KIT proto?Oncogene Receptor Tyrosine Kinase, KRAS: v?Ki?ras2 Kirsten rat sarcoma viral oncogene 
homolog, MET: tyrosine?protein kinase Met/hepatocyte growth factor receptor, NRAS: neuroblastoma RAS 
viral oncogene homolog, PDGFRa: platelet derived growth factor receptor alpha, PIK3CA: 
phosphatidylinositol?4,5?bisphosphate 3?kinase catalytic subunit alpha, RET: ret proto?oncogene, TP53: tumor 
protein p53. 
 
Supplementary Table S2) Detailed information on genetic alterations in urachal adenocarcinomas, 
squamous cell carcinomas (SCC), urothelial carcinoma (UC), and undifferentiated carcinoma (undiff. 
Ca) 
UKE analysis: Analysis of the first cohort at the University Hospital Essen, NKI: Analysis of the second cohort 
at the Netherlands Cancer Institute (NKI) Amsterdam   
 
Supplementary Table S3) Detailed clinicopathological data separately displayed for both cohorts 
UrC: urachal cancer, LN: lymph node, Dist. met.: distant metastasis, NOS: not otherwise specified, LND: 
lymph node dissection 
 
Supplementary Table S4) Protocol information regarding immunohistochemistry 
 
Supplementary Table S5) Protocol information regarding microsatellite instability analyses 
           
Supplementary Figure S1) Distribution of MAPK" and PI3K pathway related mutations in the cohort of 
urachal adenocarcinomas 
The included table displays the frequency and predicted oncological significance of the detected mutations.  
 
Supplementary Figure S2) Urachal adenocarcinomas with amplification/increased expression of  
(A"C), /HER2 (D"F) and 	
/c"MET (G"i) 
A) A tumor with 35?fold 	 amplification shows intestinal histology in hematoxylin & eosin (H&E) staining 
and strong membranous EGFR?immunostaining (H?Score: 300) in all tumor cells (B). In 	?FISH analysis 
(C), the case displayed 	?signal clustering in a majority of tumor cells with an 	"(?ratio of 29.  
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D) A tumor with 28?fold  amplification shows intestinal histology in H&E staining. A strong lateral and 
basolateral membranous HER2 immunoreactivity (E) is observed in the majority of tumor cells (score: 3+). 
#CISH?analysis (F) exhibits gene amplification with an "
(?ratio of 2.5.  
G) A tumor with 10?fold  amplification shows mucinous histology with predominant signet ring cell 
morphology in H&E staining. A moderate to strong c?MET?immunostaining (H) is noted (H?Score: 240) with 
?gene amplification and clustering in the majority of tumor cells with an "(?ratio of 4.9 (i).   
Magnifications: all H&E and IHC images: 200x; CISH?image: 400x; FISH?images: 1000x. 
 
Supplementary Figure S3) Overall (a) and recurrence"free (b) survival Kaplan"Meier plots 
p?values result from Log?rank tests. 
 
Supplementary Figure S4) Distribution of molecular alterations in urachal (UrC) and colorectal (CRC) 
adenocarcinomas and urothelial bladder cancer (UC) 
UrC data derives from the present study. Data on CRC and UC is derived from The Cancer Genome Atlas 
(TCGA) publications. 
28, 40
 
 
Supplementary Document S1) More detailed information on Material and Methods used in urachal 
adenocarcinomas separately displayed for each analyzed cohort. 
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A 
B UrC type
Case# 14 17 29 15 2 36 38 4 5 7 11 13 21 31 37 41 23 30 34 1 8 9 19 20 22 24 25 26 33 39 40 3 6 10 12 16 18 27 28 32 35
Gender
Histology
PD-L1
Gene total (%)
BRAF 1/41 (2%)
DDR2 0/41 (0%)
EGFR 2/41 (5%)
ERBB2 1/41 (2%)
FGFR1 0/41 (0%)
FGFR3 0/41 (0%)
HRAS 0/41 (0%)
KIT 0/41 (0%)
KRAS 12/41 (29%)
MET 1/41 (2%)
NRAS 0/41 (0%)
PDGFRa 0/41 (0%)
PIK3CA 2/41 (5%)
RET 0/41 (0%)
TP53 24/41 (59%)
Histology
UrC type UC UD mucinous*
Case# 54 59 61 51 56 66 52 50 70 72 47 48 49 53 55 58 60 62 63 65 67 69 71 73 46 57 64 68 74 42 43 44 45 intestinal
Gender NOS
Histology mixed
PD-L1 Gender
Gene male
BRAF female
EGFR PD-L1 TPS
FGFR1 n/a
FGFR3 <1%
HRAS 1-49%
KIT ≥ 50%
KRAS Gen. classifier
MET missense 
NRAS nonsense
PDGFRa deletion
PIK3CA insertion
TP53 splice-site
amplification
1/29 (3%)
0/29 (0%)
0/29 (0%)
3/29 (10%)
2/29 (7%)
0/29 (0%)
0/29 (0%)
22/29 (76%)
1/29 (3%)
1/29 (3%)
1/29 (3%)
1/29 (3%)
total (%)
SCC
Adenocarcinomas
UK Essen analysis
non-ADCNKI Amsterdam analysis
Adenocarcinomas
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